TB PRACTECAL | A cutting-edge clinical trial

TB PRACTECAL is an MSF-sponsored clinical trial that's evaluating new approaches to combat drug-resistant tuberculosis (TB).

Know as DR-TB, this strain of the disease does not respond to first-line antibiotics and can require an arduous treatment.

"The side effects of the medicines people currently take are often described as worse than the disease itself: nausea, headaches, deafness, psychosis," says Bern-Thomas Nyang'wa, who leads the study.

"Patients have to take up to 20 pills a day, alongside painful injections, and treatment can last more than two years."

An estimated 600,000 people worldwide are living with multidrug-resistant or extremely drug-resistant TB.

The TB PRACTECAL trial has sites around the world, currently monitoring over 100 patients in the search to find a less toxic treatment for those affected by the disease.

More about tuberculosis >

Featured videos

Embedded thumbnail for Plague | A survivor's story from Madagascar

Plague | A survivor's story from Madagascar

Embedded thumbnail for Innovation | Fast and flexible modular hospitals

Innovation | Fast and flexible modular hospitals

Embedded thumbnail for Colombia | "He showed me his gun and gave the order to his companion"

Colombia | "He showed me his gun and gave the order to his companion"

Embedded thumbnail for MSF in 2017 | Thank you for your support this year

MSF in 2017 | Thank you for your support this year